{
    "clinical_study": {
        "@rank": "161272", 
        "acronym": "RING", 
        "arm_group": [
            {
                "arm_group_label": "RTX group", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will receive a RTX infusion (1g) at w0, w2, w24, w26, w48, w50, w72 and w74"
            }, 
            {
                "arm_group_label": "Control group", 
                "arm_group_type": "Active Comparator", 
                "description": "Subjects will not receive RTX infusions and will be followed in standard of care"
            }
        ], 
        "brief_summary": {
            "textblock": "OBJECTIVE To test whether Rituximab (RTX) is efficacious to achieve complete renal response\n      (CR) in Lupus Nephritis (LN) patients with persistent proteinuria (\u22651g/d) despite at least 6\n      months of standard of care (SOC).\n\n      STUDY DESIGN Investigator-initiated randomized international open multicentric 104-week\n      study."
        }, 
        "brief_title": "RING - Rituximab for Lupus Nephritis With Remission as a Goal", 
        "completion_date": {
            "#text": "November 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Lupus Nephritis", 
        "condition_browse": {
            "mesh_term": [
                "Lupus Nephritis", 
                "Nephritis"
            ]
        }, 
        "detailed_description": {
            "textblock": "After screening (week -8), patients enter in a run-in period of 6 weeks during which\n      treatment is unchanged. At week -2, if persistent proteinuria is confirmed (uP/C ratio \u22651\n      expressed in mg/mg), patients will be randomized in a 1/1 ratio to 1 of 2 treatment groups\n      as follows :\n\n      RTX group Subjects will receive a RTX infusion (1g) at w0, w2, w24, w26, w48, w50,w72 and\n      w74.Control group Subjects will not receive RTX infusions. In both arms, azathioprine (AZA)\n      or mycophenolate mofetil (MMF) will be continued. If prescribed, prednisolone dose should\n      not be > 10 mg/day."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        All the following inclusion criteria are to be met :\n\n          1. SLE, according to ACR and/or SLICC (Arthritis Rheum 2012; May 2; doi:\n             10.1002/art.34473) criteria ;\n\n          2. Age \u226515y (except if local ethics committee imposes \u226518y) ;\n\n          3. ISN/RPS 2003 Class III (A or A/C), IV (A or A/C ; S or G) or V lupus GN confirmed on\n             renal biopsy performed within 24 months before screening ;\n\n          4. Having received one out of four following immunosuppressive regimens:\n\n             i): Euro-Lupus (EL) intravenous (IV) cyclophosphamide (CY) (6x 500 mg q2w) followed\n             by AZA/MMF for 3 months ; ii): NIH IVCY for 6M (6 monthly pulses) followed by AZA/MMF\n             for 3 months ; iii): MMF for at least 6 months at a dose of 2g/day (or the maximal\n             tolerated dose; iv):  AZA for at least 6 months at a dose of 2 mg/kg/day (or the\n             maximal toerated dose).\n\n             All patients should be on AZA or MMF at screening. In all regimens, MMF can be\n             replaced by enteric-coated mycophenolic acid (eMPA) ;\n\n          5. If on GC, being on maximum 10 mg equivalent prednisolone/d at screening (for at least\n             2 weeks) ;\n\n          6. uP/C ratio \u22651 (expressed in mg/mg) measured in a 24-h urine collection, confirmed at\n             randomization (w-2) ;\n\n          7. Contraception (any type ; sexual abstinence is an alternative to contraception in\n             paediatric patients) ;\n\n          8. Signed informed consent (drafted according to local practice and approved by the\n             local ethics committee).\n\n        Exclusion Criteria:\n\n        Any of the following :\n\n          1. Recent or ongoing renal flare defined as either i) : fall in estimated glomerular\n             filtration rate (eGFR ; MDRD) \u226525% within 3 month prior to screening or between\n             screening and randomization ; or ii) : increase in urine protein by \u2265100% to >3.5g/d\n             compared to previous assessment ;\n\n          2. 24-h proteinuria decline >50% over previous 6 months ;\n\n          3. Treatment with \u226510 mg equivalent prednisolone/d in the last 2 weeks before screening\n             ;\n\n          4. Pregnancy or breast-feeding ;\n\n          5. Anticipated non-compliance with the protocol ;\n\n          6. History of malignancy (except non-melanoma skin and cervical intraepithelial cancer)\n             ;\n\n          7. Previous treatment with RTX (whenever) and previous treatment with another biologic\n             agent within the last 6 months ;\n\n          8. HIV infection ;\n\n          9. Active HBV/HCV/TB infection ;\n\n         10. Severe liver, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic,\n             haematologic or psychiatric disturbances, that would contraindicate inclusion in the\n             protocol, as judged by the clinician."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "15 Years"
        }, 
        "enrollment": {
            "#text": "194", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 22, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01673295", 
            "org_study_id": "P1200_11"
        }, 
        "intervention": [
            {
                "arm_group_label": "RTX group", 
                "description": "RTX + Standard of Care", 
                "intervention_name": "RTX  infusions", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Control group", 
                "description": "Standard of Care only", 
                "intervention_name": "Standard of Care", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Rituximab"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Lupus Nephritis", 
            "Rituximab"
        ], 
        "lastchanged_date": "August 27, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Bruxelles", 
                    "country": "Belgium", 
                    "zip": "1200"
                }, 
                "name": "Cliniques Universitaires Saint Luc"
            }
        }, 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_arms": "2", 
        "official_title": "RING - Rituximab for Lupus Nephritis With Remission as a Goal, an Investigator-initiated Randomized International Open Multicentric Study", 
        "overall_contact": {
            "email": "frederic.houssiau@uclouvain.be", 
            "last_name": "Fr\u00e9d\u00e9ric A Houssiau, MD PHD", 
            "phone": "+32 2 7645391"
        }, 
        "overall_contact_backup": {
            "email": "genevieve.depresseux@uclouvain.be", 
            "last_name": "Genevi\u00e8ve J Depresseux, Trial Coord", 
            "phone": "+32 2 7645395"
        }, 
        "overall_official": {
            "affiliation": "Cliniques universitaires Saint-Luc", 
            "last_name": "Fr\u00e9d\u00e9ric A Houssiau, MD PHD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Belgium: Federal Agency for Medicinal Products and Health Products", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "CR is defined as :\nuP/C ratio \u22640.5 (expressed in mg/mg) measured in a 24-h urine collection; and\neGFR >=60ml/min or, if <60ml/min at screening, not fallen by >20% compared to screening; and\nno increase of glucocortico\u00efds (GC) throughout the study (except for two limited courses as per protocol; vide infra); and\nno introduction of another immunosuppressant.", 
            "measure": "The primary endpoint is the percentage of patients achieving renal complete response (CR) at w104.", 
            "safety_issue": "Yes", 
            "time_frame": "104 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01673295"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Universit\u00e9 Catholique de Louvain", 
            "investigator_full_name": "Fr\u00e9d\u00e9ric A. Houssiau, MD, PhD", 
            "investigator_title": "Professeur Ordinaire, Chef de Service Clinique", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "source": "Universit\u00e9 Catholique de Louvain", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "European Working Party on Systemic Lupus Erythematosus", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Lupus Nephritis Trial Network", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Fr\u00e9d\u00e9ric A. Houssiau, MD, PhD", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2012"
    }
}